This study is a clinical trial designed to assess whether fish oil treatments are effective
in the prevention of obesity-related fat tissue (adipose) inflammation. Specifically it
addresses the hypothesis that fish oils treatments will reduce signaling by chemokine
pathways (fractalkine and MCP-1) important in adipose tissue for the recruitment and
activation of certain white blood cells (macrophages). The study is a double-blind
placebo-controlled trial of the fish oil Lovaza from GlaxoSmithKline (omega-3-acid ethyl
esters; a combination of ethyl esters of eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA)) in obese non-diabetic adults, to determine if Lovaza decreases markers of inflammation
and macrophage activation in adipose and blood and understand the mechanism by which fish
oils affect inflammation.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)